Steward Partners Investment Advisory, LLC Chemo Centryx, Inc. Transaction History

Steward Partners Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$22.17 - $51.8 $336,363 - $785,909	-15,172 Reduced 92.6%	1,212 $63,000
Q2 2022 Aug 04, 2022	BUY	$15.36 - $27.51 $46,878 - $83,960	3,052 Added 22.89%	16,384 $406,000
Q1 2022 May 02, 2022	BUY	$22.22 - $39.12 $37,751 - $66,464	1,699 Added 14.61%	13,332 $334,000
Q4 2021 Feb 08, 2022	SELL	$18.38 - $40.5 $215,174 - $474,133	-11,707 Reduced 50.16%	11,633 $424,000
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $172,842 - $260,050	13,114 Added 128.24%	23,340 $399,000
Q2 2021 Aug 13, 2021	SELL	$9.59 - $50.88 $12,505 - $66,347	-1,304 Reduced 11.31%	10,226 $137,000
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $364,689 - $503,629	7,363 Added 176.7%	11,530 $590,000
Q4 2020 Feb 11, 2021	BUY	$47.25 - $65.16 $77,301 - $106,601	1,636 Added 64.64%	4,167 $258,000
Q3 2020 Oct 30, 2020	BUY	$46.35 - $61.69 $75,457 - $100,431	1,628 Added 180.29%	2,531 $139,000
Q2 2020 Aug 06, 2020	BUY	$38.58 - $65.07 $24,961 - $42,100	647 Added 252.73%	903 $52,000
Q1 2020 Apr 29, 2020	BUY	$32.73 - $50.78 $8,378 - $12,999	256 New	256 $10,000

66.3K

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.